Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Via Therapeutics, LLC secured a $971,316 NIH SBIR/STTR award: Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza

Sep 01, 2026•about 4 hours ago
United States

Description

PROJECT SUMMARY TFF Pharmaceuticals (TFFP) is developing a shelf-stable thin-film freeze (TFF) dry powder universal flu vaccine. Commercialization of this product would provide the first vaccine that is at least 75% effective against symptomatic influenza virus infection, with the added benefit of easy delivery and storage at room temperature to facilitate broad, cost-effective distribution. With NIAID’s Collaborative Influenza Vaccine Innovation Center funding, the University of Georgia (UGA) h

Company Information

Company

Via Therapeutics

Location

United States

About

Via Therapeutics is an expert-led drug delivery and formulation development partner helping companies advance complex molecules from early concept toward the clinic. Our team works directly with clients to solve formulation challenges, shape development strategy, and reduce risk across the product development pathway. We support advanced delivery approaches including inhaled and nasal products, topical and transdermal systems, long-acting injectables, pediatric oral dosage forms, poorly water-soluble drugs, vaccines, infectious disease programs, analytical services, and SBIR/STTR consulting. From concept to clinic, Via Therapeutics helps make molecules work through smarter drug delivery. Want to connect? Visit https://www.viatherapeutics.com/

Predictive Intelligence
Strategic

ML-powered predictions for Via Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Via Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.